PERTH, Australia--(BUSINESS WIRE)--Cancer patients being treated at Icon Group’s Icon Cancer Centre Midland are now benefitting from the latest state-of-the-art radiation treatment planning and delivery technology with the introduction of Varian’s RapidArc Dynamic solution.
Headquartered in Brisbane, Australia, Icon Group is a leading integrated cancer care provider with a growing global reach across Australia, New Zealand, Asia, and the United Kingdom. The decision to embrace RapidArc Dynamic was driven by strong early results showing faster treatment planning, reduced radiation exposure to healthy organs, and potential to set new standards in patient-centred care.
Icon is the first in the Southern Hemisphere and only the third worldwide to clinically treat with RapidArc Dynamic, marking a major step forward in radiation therapy, particularly for patients with breast and prostate cancer.
The introduction of RapidArc Dynamic technology at Icon has yielded significant data-driven improvements in treatment planning and execution including:
Treatment Planning Efficiency: With the use of advanced deterministic algorithms that automate key planning processes, RapidArc Dynamic has achieved up to an 80% reduction in treatment planning time for breast radiotherapy. This innovation enables clinicians to streamline treatment design, further reducing the number of arcs required from up to five down to a single arc per plan.
Reduced Radiation to Organs at Risk (OAR): Reduced radiation exposure to critical organs. For example, the mean dose to the heart has dropped by an average of 22%, lowering the risk of side effects and improving patients' quality of life.
Physician Confidence in Treatment Plans: In a recent blinded physician review, RapidArc Dynamic-based plans were selected as optimal in 100% of cases, demonstrating broad clinical confidence in the technology's ability to enhance plan quality and potentially yield better patient outcomes.
Prof. John Boyages AM, Icon Radiation Oncologist involved in RapidArc Dynamic’s early plan quality evaluations, highlighted the clinical impact of this technology.
“I’m really excited about this technology. We already have some of the best treatment plans I’ve seen in my 40-year career at Icon, and this has just taken it to another level. I’m blown away by the ability to curve radiation around healthy organs and reduce doses to tissues like the heart to very safe levels whilst giving the right doses to the cancer areas,” said Prof. Boyages.
